Results 251 to 257 of about 27,503 (257)

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis

Annals of Pharmacotherapy, 2012
Karen Rascati, Chanhyun Park, Haesuk Park   +2 more
exaly  

Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes

Expert Opinion on Pharmacotherapy, 2016
Jingbo Hu, Xueying Tan
exaly  

Alogliptin, a Dipeptidyl Peptidase‐4 Inhibitor, Alleviates Atrial Remodeling and Improves Mitochondrial Function and Biogenesis in Diabetic Rabbits

Journal of the American Heart Association, 2017
Xue Liang
exaly  

Synthesis of a Dipeptidyl Peptidase-4 Inhibitor

Synfacts, 2014
openaire   +1 more source

A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.

Journal of the American College of Cardiology, 2012
Eiichi Akiyama, Taishi Nakamura, Shokei Kim-Mitsuyama   +2 more
exaly  

Dipeptidyl Peptidase 4 Inhibitor–Associated Bullous Pemphigoid

Mayo Clinic Proceedings
Shohei Kitayama, Teruhiko Makino, Tadamichi Shimizu   +2 more
openaire   +2 more sources

Dipeptidyl-Peptidase 4 (DPP4) Inhibitors

openaire   +1 more source